Aakaar Medical Technologies

Aakaar Medical reported FY26 revenue of ₹66.9 croreCurrent reported value: ₹66.9 crore. No comparable prior figure is available in the source record. (up 8.6Current reported value: 8.6. No comparable prior figure is available in the source record.% YoY) with EBITDA of ₹10.97 croreCurrent reported value: ₹10.97 crore. No comparable prior figure is available in the source record. and PAT of ₹6.6 croreCurrent reported value: ₹6.6 crore. No comparable prior figure is available in the source record., both at record levels. H2 revenue surged 64% over H1 to ₹41.63 crore, driven by deliberate H1 credit tightening that improved collections and reduced debtor days from 209 to 167. Gross margins expanded from 54% to 59% as own-brand contribution rose to 37%Current 37%. Reported change: +3pp YoY.. Management reiterated a 30%+ CAGRCurrent reported value: 30%+ CAGR. No comparable prior figure is available in the source record. target and aims for main board listing within three years. New product launches (Latigo botulinum toxin, VM exosomes) and the Zelix clinic platform (16 clinics onboarded, targeting 50 by year-end) provide growth levers. Risk: working capital remains structurally high; IPO proceeds of ₹20 crore are earmarked for rationalization, but cash conversion may lag if distributor model transition falters.